CVS Health's Financial Performance Continues to Improve
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: NASDAQ.COM
- Financial Recovery: CVS Health's revenue increased by approximately 6% year-over-year to $100.4 billion in Q1, with adjusted earnings per share rising 14% to $2.57, indicating a gradual recovery in profitability post-pandemic, which boosts investor confidence.
- Declining Medical Benefit Ratio: The medical benefit ratio (MBR) dropped to 84.6%, down 2.7% from Q1 2025, suggesting improved efficiency in healthcare spending, which enhances overall profit margins and reflects effective cost management.
- Successful Digital Transformation: By digitizing the prior authorization process, CVS Health has improved the efficiency of its insurance business, helping to control costs and increase profits, indicating that the company's strategic focus on technology investment is paying off.
- Long-term Investment Appeal: CVS Health has increased its dividends by 56.5% over the past decade, with a forward dividend yield of 2.6%, and is trading at 13.8 times forward earnings, below the healthcare sector average of 17.4 times, highlighting its attractiveness for long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to fall
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 99.160
Low
91.00
Averages
96.71
High
105.00
Current: 99.160
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer CFO Dave Denton Resigns to Join Consumer Goods Sector
- Executive Departure: Pfizer's CFO Dave Denton will resign on August 15 to pursue a role in the consumer goods sector, indicating increased executive turnover that may affect investor confidence.
- Interim Appointment: Pfizer has appointed Cecile Guegan, senior vice president of finance for its global biopharmaceutical business, as interim CFO effective August 16, ensuring continuity in financial management and reducing uncertainty associated with executive transitions.
- Past Achievements: Since joining Pfizer in 2022, Denton has been instrumental in major transactions, including the acquisitions of cancer therapy specialist Seagen, migraine drugmaker Biohaven, and obesity drug developer Metsera, enhancing the company's competitive position in the market.
- Market Reaction: Following the announcement of Denton's resignation, Pfizer's shares fell 1.6% in premarket trading, reflecting market concerns over executive changes that could impact the company's future financial performance.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
CVS Health's Financial Performance Continues to Improve
- Financial Recovery: CVS Health's revenue increased by approximately 6% year-over-year to $100.4 billion in Q1, with adjusted earnings per share rising 14% to $2.57, indicating a gradual recovery in profitability post-pandemic, which boosts investor confidence.
- Declining Medical Benefit Ratio: The medical benefit ratio (MBR) dropped to 84.6%, down 2.7% from Q1 2025, suggesting improved efficiency in healthcare spending, which enhances overall profit margins and reflects effective cost management.
- Successful Digital Transformation: By digitizing the prior authorization process, CVS Health has improved the efficiency of its insurance business, helping to control costs and increase profits, indicating that the company's strategic focus on technology investment is paying off.
- Long-term Investment Appeal: CVS Health has increased its dividends by 56.5% over the past decade, with a forward dividend yield of 2.6%, and is trading at 13.8 times forward earnings, below the healthcare sector average of 17.4 times, highlighting its attractiveness for long-term investors.
See More
CVS Health Shows Strong Recovery Momentum
- Financial Recovery: In Q1, CVS Health's revenue increased by approximately 6% year-over-year to $100.4 billion, with adjusted EPS rising 14% to $2.57, surpassing analyst expectations and indicating a gradual recovery in profitability post-pandemic.
- Improved Medical Benefit Ratio: The medical benefit ratio (MBR) dropped to 84.6%, down 2.7% from Q1 2025, indicating enhanced efficiency in healthcare spending, which contributes positively to overall profit margins.
- Digital Transformation Efforts: CVS Health has improved the efficiency of its insurance business by digitizing the prior authorization process, which not only helps control costs but also boosts the company's profitability, showcasing its competitive edge in the industry.
- Long-Term Growth Potential: CVS Health's diversified healthcare model allows it to support patients throughout their care journey, and combined with its strong brand trust, it is well-positioned to benefit from global aging trends that will drive increased healthcare spending in the future.
See More
CVS Health Stock Surges on Medicare Developments
- Stock Recovery: After a rough start to 2026, CVS Health shares have surged over 25% recently due to promising Medicare-related developments, indicating a strong market rebound that boosts investor confidence.
- Analyst Target Increase: Mizuho analyst Ann Hynes raised CVS's price target from $110 to $115, presenting about a 13% upside from the current price of $100.68, reflecting optimistic market expectations for CVS's future performance.
- Investor Sentiment Shift: As the stock price rises, investors are increasingly confident that CVS can continue to exceed expectations, moving beyond merely anticipating “better than expected” results, which could drive further price increases.
- Valuation Potential: Currently trading at a forward P/E of 13.8, if CVS reaches $115 with projected earnings of $7.43 per share in 2026, the P/E would rise to 15.5, suggesting that a revaluation could push the stock price closer to $150.
See More
Mizuho Raises CVS Price Target to $115
- Price Target Increase: Mizuho analyst Ann Hynes raised CVS Health's price target from $110 to $115, implying a potential upside of approximately 13%, reflecting market optimism regarding CVS's future performance.
- Stock Recovery: After a rough start to 2026, CVS Health's shares have surged over 25%, indicating increased investor confidence in the company's promising developments related to Medicare, suggesting it may continue to exceed market expectations.
- Valuation Potential: Currently trading at about 13.8 times forward earnings, if CVS's stock rises to $115, based on a forecasted earnings of $7.43 per share for 2026, it would imply a forward multiple of 15.5, showcasing CVS's competitive edge and growth potential in the healthcare sector.
- Market Perception Shift: As CVS is recognized as a diversified healthcare services company, market understanding of its valuation is aligning more closely with that of UnitedHealth Group, and if CVS's forward multiple rises to as high as 20 times, its stock price could approach $150, further solidifying its status as a blue-chip stock.
See More
Pfizer CFO Dave Denton Resigns to Join Consumer Goods Sector
- Executive Departure: Pfizer's CFO Dave Denton will resign on August 15 to pursue a role in the consumer goods sector, indicating increased executive turnover that may affect investor confidence.
- Interim Appointment: Pfizer has appointed Cecile Guegan, senior vice president of finance for its global biopharmaceutical business, as interim CFO effective August 16, ensuring continuity in financial management and reducing uncertainty associated with executive transitions.
- Past Achievements: Since joining Pfizer in 2022, Denton has been instrumental in major transactions, including the acquisitions of cancer therapy specialist Seagen, migraine drugmaker Biohaven, and obesity drug developer Metsera, enhancing the company's competitive position in the market.
- Market Reaction: Following the announcement of Denton's resignation, Pfizer's shares fell 1.6% in premarket trading, reflecting market concerns over executive changes that could impact the company's future financial performance.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
CVS Health's Financial Performance Continues to Improve
- Financial Recovery: CVS Health's revenue increased by approximately 6% year-over-year to $100.4 billion in Q1, with adjusted earnings per share rising 14% to $2.57, indicating a gradual recovery in profitability post-pandemic, which boosts investor confidence.
- Declining Medical Benefit Ratio: The medical benefit ratio (MBR) dropped to 84.6%, down 2.7% from Q1 2025, suggesting improved efficiency in healthcare spending, which enhances overall profit margins and reflects effective cost management.
- Successful Digital Transformation: By digitizing the prior authorization process, CVS Health has improved the efficiency of its insurance business, helping to control costs and increase profits, indicating that the company's strategic focus on technology investment is paying off.
- Long-term Investment Appeal: CVS Health has increased its dividends by 56.5% over the past decade, with a forward dividend yield of 2.6%, and is trading at 13.8 times forward earnings, below the healthcare sector average of 17.4 times, highlighting its attractiveness for long-term investors.
See More
CVS Health Shows Strong Recovery Momentum
- Financial Recovery: In Q1, CVS Health's revenue increased by approximately 6% year-over-year to $100.4 billion, with adjusted EPS rising 14% to $2.57, surpassing analyst expectations and indicating a gradual recovery in profitability post-pandemic.
- Improved Medical Benefit Ratio: The medical benefit ratio (MBR) dropped to 84.6%, down 2.7% from Q1 2025, indicating enhanced efficiency in healthcare spending, which contributes positively to overall profit margins.
- Digital Transformation Efforts: CVS Health has improved the efficiency of its insurance business by digitizing the prior authorization process, which not only helps control costs but also boosts the company's profitability, showcasing its competitive edge in the industry.
- Long-Term Growth Potential: CVS Health's diversified healthcare model allows it to support patients throughout their care journey, and combined with its strong brand trust, it is well-positioned to benefit from global aging trends that will drive increased healthcare spending in the future.
See More
CVS Health Stock Surges on Medicare Developments
- Stock Recovery: After a rough start to 2026, CVS Health shares have surged over 25% recently due to promising Medicare-related developments, indicating a strong market rebound that boosts investor confidence.
- Analyst Target Increase: Mizuho analyst Ann Hynes raised CVS's price target from $110 to $115, presenting about a 13% upside from the current price of $100.68, reflecting optimistic market expectations for CVS's future performance.
- Investor Sentiment Shift: As the stock price rises, investors are increasingly confident that CVS can continue to exceed expectations, moving beyond merely anticipating “better than expected” results, which could drive further price increases.
- Valuation Potential: Currently trading at a forward P/E of 13.8, if CVS reaches $115 with projected earnings of $7.43 per share in 2026, the P/E would rise to 15.5, suggesting that a revaluation could push the stock price closer to $150.
See More
Mizuho Raises CVS Price Target to $115
- Price Target Increase: Mizuho analyst Ann Hynes raised CVS Health's price target from $110 to $115, implying a potential upside of approximately 13%, reflecting market optimism regarding CVS's future performance.
- Stock Recovery: After a rough start to 2026, CVS Health's shares have surged over 25%, indicating increased investor confidence in the company's promising developments related to Medicare, suggesting it may continue to exceed market expectations.
- Valuation Potential: Currently trading at about 13.8 times forward earnings, if CVS's stock rises to $115, based on a forecasted earnings of $7.43 per share for 2026, it would imply a forward multiple of 15.5, showcasing CVS's competitive edge and growth potential in the healthcare sector.
- Market Perception Shift: As CVS is recognized as a diversified healthcare services company, market understanding of its valuation is aligning more closely with that of UnitedHealth Group, and if CVS's forward multiple rises to as high as 20 times, its stock price could approach $150, further solidifying its status as a blue-chip stock.
See More
